NICE no for Roche's Avastin for breast cancer
This article was originally published in Scrip
NICE, the National Institute for health and Clinical Excellence, said in draft guidance on 9 July that it was not inclined to recommend Roche's VEGF-targeted Avastin (bevacizumab), in combination with a taxane, as a first line treatment for metastatic breast cancer for NHS patients in England and Wales.
You may also be interested in...
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.
In an exclusive interview, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.
Criticism of Novartis/Avexis’s controversial lottery style managed access program for Zolgensma has come largely from Europe, while other countries in Latin America and Asia have been far more receptive.